boceprevir (SCH 503034)

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chronic Hepatitis CHepatitis C, Chronic

Phase 2

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

CompletedNCT00423670

Merck Sharp & Dohme LLCChronic Hepatitis C

Start: 2007-01-31End: 2008-11-30Updated: 2017-04-05

Phase 3

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

CompletedNCT00708500

Merck Sharp & Dohme LLCHepatitis C, Chronic

Start: 2008-08-31End: 2010-04-30Updated: 2017-04-07

Related Papers

Boceprevir for previously treated chronic HCV genotype 1 infection.

2011-03-011158 citations

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

2010-08-06482 citations